BR112021020401A2 - Sistema de dois plasmídeos, plasmídeo auxiliar, plasmídeo vetor, usos do sistema de dois plasmídeos, métodos para controlar ou maximizar a razão de partículas completas para totais produzidas durante a produção de aav recombinante e para aumentar, otimizar ou maximizar o rendimento de aav recombinante - Google Patents
Sistema de dois plasmídeos, plasmídeo auxiliar, plasmídeo vetor, usos do sistema de dois plasmídeos, métodos para controlar ou maximizar a razão de partículas completas para totais produzidas durante a produção de aav recombinante e para aumentar, otimizar ou maximizar o rendimento de aav recombinanteInfo
- Publication number
- BR112021020401A2 BR112021020401A2 BR112021020401A BR112021020401A BR112021020401A2 BR 112021020401 A2 BR112021020401 A2 BR 112021020401A2 BR 112021020401 A BR112021020401 A BR 112021020401A BR 112021020401 A BR112021020401 A BR 112021020401A BR 112021020401 A2 BR112021020401 A2 BR 112021020401A2
- Authority
- BR
- Brazil
- Prior art keywords
- plasmid
- maximizing
- recombinant aav
- methods
- optimizing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1905263.8A GB201905263D0 (en) | 2019-04-12 | 2019-04-12 | Plasmid system |
| EP19169121.1A EP3722434B2 (en) | 2019-04-12 | 2019-04-12 | Plasmid system |
| PCT/GB2020/050947 WO2020208379A1 (en) | 2019-04-12 | 2020-04-14 | Plasmid system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020401A2 true BR112021020401A2 (pt) | 2021-12-07 |
Family
ID=70295566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020401A BR112021020401A2 (pt) | 2019-04-12 | 2020-04-14 | Sistema de dois plasmídeos, plasmídeo auxiliar, plasmídeo vetor, usos do sistema de dois plasmídeos, métodos para controlar ou maximizar a razão de partículas completas para totais produzidas durante a produção de aav recombinante e para aumentar, otimizar ou maximizar o rendimento de aav recombinante |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220162642A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3953482A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7562558B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20220019669A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113891942A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020272557B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021020401A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3136545A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL296544A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202111149VA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020208379A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020001593A (es) | 2017-08-09 | 2020-07-13 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y usos de las mismas. |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| PL3722434T3 (pl) | 2019-04-12 | 2022-12-12 | Freeline Therapeutics Limited | Układ plazmidowy |
| WO2021084276A2 (en) | 2019-11-01 | 2021-05-06 | Freeline Therapeutics Limited | Factor viii construct |
| WO2022159702A1 (en) * | 2021-01-22 | 2022-07-28 | Biogen Ma Inc. | Microtubule destabilizer additives to increase recombinant viral vector titers |
| WO2022182986A1 (en) * | 2021-02-26 | 2022-09-01 | Logicbio Therapeutics, Inc. | Manufacturing and use of recombinant aav vectors |
| EP4410971A4 (en) * | 2021-09-30 | 2025-06-04 | FUJIFILM Corporation | METHOD FOR PRODUCING AN ADENO-ASSOCIATED VIRUS, CELLS AND EXPRESSION VECTOR |
| GB202214328D0 (en) | 2022-09-29 | 2022-11-16 | Freeline Therapeutics Ltd | Method |
| WO2024160232A1 (zh) * | 2023-02-01 | 2024-08-08 | 纽福斯(苏州)生物科技有限公司 | 质粒包装系统及其应用 |
| CN118633572B (zh) * | 2023-03-06 | 2026-07-21 | 北京锦篮基因科技股份有限公司 | 神经元核内包涵体病小鼠模型构建方法及应用 |
| WO2024223931A1 (en) * | 2023-04-28 | 2024-10-31 | AstraZeneca Ireland Limited | Manufacturing and use of recombinant self-complementary aav vectors |
| KR20260082361A (ko) | 2023-08-31 | 2026-06-04 | 디노 테라퓨틱스, 인코포레이티드 | 캡시드 폴리펩타이드 및 이의 사용 방법 |
| WO2025083617A1 (en) * | 2023-10-18 | 2025-04-24 | Nanocell Therapeutics Holdings B.V. | Methods and compositions for nucleic construct delivery |
| TW202545971A (zh) | 2024-02-08 | 2025-12-01 | 美商戴諾治療公司 | 殼體多肽及其使用方法 |
| TW202548023A (zh) | 2024-03-14 | 2025-12-16 | 美商雅菲納治療公司 | 用於生產重組腺相關病毒的質體系統 |
| EP4628576A1 (en) | 2024-04-07 | 2025-10-08 | Ascend Advanced Therapies GmbH | Microrna molecules for use in methods for improving recombinant aav production |
| WO2025238067A1 (en) | 2024-05-15 | 2025-11-20 | Ascend Advanced Therapies Gmbh | Novel vector system for aav production |
| EP4752226A1 (en) | 2024-11-28 | 2026-06-03 | Ascend Advanced Therapies GmbH | Plasmid system for aav production |
| WO2026064428A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026064444A1 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026064442A2 (en) | 2024-09-18 | 2026-03-26 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
| WO2026109693A1 (en) | 2024-11-21 | 2026-05-28 | Ascend Advanced Therapies Ltd | Method for improved aav production |
| WO2026122963A1 (en) | 2024-12-06 | 2026-06-11 | Dyno Therapeutics, Inc. | Capsid polypeptides and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10066104A1 (de) | 2000-09-08 | 2003-01-09 | Medigene Ag | Wirtszellen zur Verpackung von rekombinantem Adeno-assoziiertem Virus (rAAV), Verfahren zu ihrer Herstellung und deren Verwendung |
| CA2453405A1 (en) * | 2001-07-13 | 2003-01-23 | University Of Iowa Research Foundation | Pseudotyped adeno-associated viruses and uses thereof |
| AU2002352195A1 (en) * | 2001-11-30 | 2003-06-10 | Medigene Aktiengesellschaft | Optimized production of viral vectors derived from paroviruses in packaging and production cells by hsv infection or treatment with dna methylation inhibitors |
| ES2330826B1 (es) * | 2008-06-04 | 2010-07-26 | Proyecto De Biomedicina Cima, S.L. | Sistema para empaquetamiento de adenovirus de alta capacidad. |
| CA2754335C (en) * | 2009-03-04 | 2019-12-24 | Medigene Ag | Assembly activating protein (aap) and its use for the manufacture of parvovirus particles essentially consisting of vp3 |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| EP2782596A4 (en) | 2011-11-22 | 2015-07-29 | Philadelphia Children Hospital | VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENIC ADMINISTRATION |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| GB201508026D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Capsid |
| WO2017096164A1 (en) | 2015-12-02 | 2017-06-08 | The Board Of Trustees Of The Leland Stanford Junior University | Novel recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism |
| CN108048483B (zh) * | 2018-01-30 | 2021-02-02 | 中国疾病预防控制中心病毒病预防控制所 | 复制型重组腺病毒HAdV-5载体系统及其应用 |
-
2020
- 2020-04-14 CA CA3136545A patent/CA3136545A1/en active Pending
- 2020-04-14 SG SG11202111149VA patent/SG11202111149VA/en unknown
- 2020-04-14 JP JP2021560095A patent/JP7562558B2/ja active Active
- 2020-04-14 US US17/602,941 patent/US20220162642A1/en not_active Abandoned
- 2020-04-14 WO PCT/GB2020/050947 patent/WO2020208379A1/en not_active Ceased
- 2020-04-14 EP EP20720111.2A patent/EP3953482A1/en active Pending
- 2020-04-14 AU AU2020272557A patent/AU2020272557B2/en active Active
- 2020-04-14 KR KR1020217037076A patent/KR20220019669A/ko active Pending
- 2020-04-14 BR BR112021020401A patent/BR112021020401A2/pt unknown
- 2020-04-14 IL IL296544A patent/IL296544A/en unknown
- 2020-04-14 CN CN202080039790.8A patent/CN113891942A/zh active Pending
-
2021
- 2021-10-07 IL IL287100A patent/IL287100A/en unknown
-
2025
- 2025-11-06 US US19/381,401 patent/US20260117255A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL296544A (en) | 2022-11-01 |
| AU2020272557A1 (en) | 2021-12-09 |
| SG11202111149VA (en) | 2021-11-29 |
| EP3953482A1 (en) | 2022-02-16 |
| US20260117255A1 (en) | 2026-04-30 |
| CN113891942A (zh) | 2022-01-04 |
| JP7562558B2 (ja) | 2024-10-07 |
| AU2020272557B2 (en) | 2026-05-28 |
| KR20220019669A (ko) | 2022-02-17 |
| CA3136545A1 (en) | 2020-10-15 |
| WO2020208379A1 (en) | 2020-10-15 |
| US20220162642A1 (en) | 2022-05-26 |
| IL287100A (en) | 2021-12-01 |
| JP2022530192A (ja) | 2022-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006646A (es) | Vector viral adenoasociado recombinante para el suministro de genes. | |
| PH12021551155A1 (en) | Recombinant viral vectors and nucleic acids for producing the same | |
| WO2019241535A3 (en) | Anion exchange chromatography for recombinant aav production | |
| EP4316512A3 (en) | Intrathecal administration of adeno-associated-viral vectors for gene therapy | |
| EP4345165A3 (en) | Gene therapy for retinitis pigmentosa | |
| MX2021003188A (es) | Composiciones y métodos para la manufactura de vectores de terapia génica. | |
| ZA202307880B (en) | Human cytomegalovirus comprising exogenous antigens | |
| EP3597760A3 (en) | Adeno-associated virus vector | |
| EA201692361A1 (ru) | Лентивирусные векторы | |
| PH12016501623A1 (en) | Compositions for the inactivation of virus replication and methods of making and using the same | |
| MX375365B (es) | Metodos mejorados para purificacion de vecotres de aav recombinantes | |
| EP4491733A3 (en) | Modulation of aav vector transgene expression | |
| MX2020009579A (es) | Vectores de adn sintetico y metodos de uso. | |
| MX2018005286A (es) | Constructo genetico. | |
| AU2017257169A1 (en) | Evasion of neutralizing antibodies by a recombinant adeno-associated virus | |
| WO2012142434A3 (en) | Aav mediated ctla-4 gene transfer to treat sjogren's syndrome | |
| EP4055174A4 (en) | TRANSGENIC CASSETTES, AAV VECTORS AND AAV VECTORS FOR EXPRESSING HUMAN CODON-OPTIMIZED SLCA1 | |
| MX2019008105A (es) | Virus. | |
| PL3740199T3 (pl) | Enkapsułkowane polimerem wektory wirusowe do terapii genetycznej | |
| ZA202304290B (en) | Nucleic acid constructs, viral vectors and viral particles | |
| BR112016023980A2 (pt) | anticorpos monoclonais recombinantes vnar que neutralizam o fator de crescimento endotelial vascular (vegf) | |
| EP4223320A3 (en) | Codon-optimized transgene for the treatment of progressive familiar intrahepatic cholestasis type 3 (pfic3) | |
| WO2020069320A4 (en) | A method for treating an auditory neuropathy spectrum disorder | |
| MX2022004770A (es) | Vectores de virus adeno-asociados (aav) para el tratamiento de la degeneracion macular relacionada con la edad y otras enfermedades y trastornos oculares. | |
| ZA202402156B (en) | Method of obtaining a modified adeno-associated virus capsid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ASCEND GENE AND CELL THERAPIES LTD (GB) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |